Literature DB >> 3599219

Vesicorenal reflux and upper urinary tract transitional cell carcinoma after transurethral resection of recurrent superficial bladder carcinoma.

J A De Torres Mateos, J M Banús Gassol, J Palou Redorta, J Morote Robles.   

Abstract

Of 288 patients with superficial transitional cell carcinoma of the bladder vesicorenal reflux developed after transurethral resection in 26 per cent. This proportion was higher (77 per cent) when we considered only those tumors located near the ureteral orifices. There was a statistically significant relationship (p less than 0.001) between the development of upper urinary tract tumors and vesicorenal reflux (20 per cent of the patients with reflux and 0.9 per cent without reflux had a tumor), which corresponds to a 22-fold greater risk in the former group. Close followup is advised, since 1 of 5 patients with reflux after transurethral resection may have upper urinary tract transitional cell carcinoma.

Entities:  

Mesh:

Year:  1987        PMID: 3599219     DOI: 10.1016/s0022-5347(17)42984-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?

Authors:  Thomasz Golabek; Joan Palou; Oscar Rodríguez; Josep Maria Gaya; Alberto Breda; Humberto Villavicencio
Journal:  World J Urol       Date:  2016-06-09       Impact factor: 4.226

2.  Needle tract seeding of transitional cell carcinoma following fine-needle aspiration of a renal mass.

Authors:  C Slywotzky; M Maya
Journal:  Abdom Imaging       Date:  1994 Mar-Apr

3.  Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study.

Authors:  Philipp Nuhn; Giacomo Novara; Christian Seitz; Amit Gupta; Kazumasa Matsumoto; Wassim Kassouf; Thomas J Walton; Hans-Martin Fritsche; Stefan Tritschler; Juan I Martínez-Salamanca; Vincenzo Ficarra; Pierre I Karakiewicz; Guido Mazzoleni; Shahrokh F Shariat; Patrick J Bastian
Journal:  World J Urol       Date:  2014-07-22       Impact factor: 4.226

4.  Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma.

Authors:  Marco Cosentino; Joan Palou; Josep M Gaya; Alberto Breda; Oscar Rodriguez-Faba; Humberto Villavicencio-Mavrich
Journal:  World J Urol       Date:  2012-05-03       Impact factor: 4.226

5.  [Superficial bladder cancer: Transurethral resection and instillation therapy].

Authors:  M Schenck; G Lümmen
Journal:  Urologe A       Date:  2015-04       Impact factor: 0.639

6.  BCG-related renal granulomas managed conservatively: A case series.

Authors:  Talal Al-Qaoud; Fadi Brimo; Armen G Aprikian; Sero Andonian
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

7.  Monitoring of the upper urinary tract in patients with bladder cancer.

Authors:  Rajinikanth Ayyathurai; Mark S Soloway
Journal:  Indian J Urol       Date:  2011-04

8.  Dynamic Change in p63 Protein Expression during Implantation of Urothelial Cancer Clusters.

Authors:  Takahiro Yoshida; Hiroaki Okuyama; Masashi Nakayama; Hiroko Endo; Yasuhiko Tomita; Norio Nonomura; Kazuo Nishimura; Masahiro Inoue
Journal:  Neoplasia       Date:  2015-07       Impact factor: 5.715

9.  Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes.

Authors:  Muammer Altok; Ali F Sahin; Mehmet I Gokce; Gokhan R Ekin; Rauf Taner Divrik
Journal:  Int Braz J Urol       Date:  2017 Nov-Dec       Impact factor: 1.541

10.  Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking history.

Authors:  Hiroki Ide; Eiji Kikuchi; Koichiro Ogihara; Naoya Niwa; Keisuke Shigeta; Tsukasa Masuda; Yuto Baba; Ryuichi Mizuno; Mototsugu Oya
Journal:  Sci Rep       Date:  2021-10-19       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.